A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma
Condition: Solitary Bone Plasmacytoma Interventions: Drug: Durvalumab; Radiation: Radiation therapy Sponsors: Memorial Sloan Kettering Cancer Center; Celgene Corporation Not yet recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials